BTIG lowered the firm’s price target on GE HealthCare (GEHC) to $87 from $89 and keeps a Buy rating on the shares following Q3 results. The firm, which thinks focus shifts to FY26, views the Street forecast for about 4% organic revenue growth with adjusted EPS of $4.93 as “achievable” given GE HealthCare’s performance history, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- Balanced Outlook on GE Healthcare Technologies Inc: Hold Recommendation Amid Market Uncertainties
- GE HealthCare price target raised to $80 from $74 at Morgan Stanley
- GE HealthCare Stock Slips Even after an Earnings Beat as Tariffs Bite
- Morning Movers: Nvidia jumps after GTC, Trump comments
- GE HealthCare reports Q3 adjusted EPS $1.07, consensus $1.05